FDA approves first pill to treat all forms of hepatitis C 

Childhood Obesity Linked to Higher Risk of Multiple Sclerosis, Possibly by Altering Vitamin D Levels
July 6, 2016
Roche’s new multiple sclerosis drug set for early FDA approval
July 7, 2016
Show all

FDA approves first pill to treat all forms of hepatitis C 

A medication that can treat all major forms of hepatitis C is now approved by the FDA.

Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.

The Food and Drug Administration approved the combination pill, Epclusa, from Gilead Sciences for patients with and without liver damage. The new drug’s broad indication could make it easier to use than five other hepatitis drugs recently approved by the FDA, which are each tailored to different viral strains or stages of liver disease.

Gilead’s previous two hepatitis drugs have raked in billions of dollars by replacing an older, less effective treatment that involved a grueling pill-and-injection cocktail. But the company’s aggressive approach to pricing has drawn scorn from patient groups, insurers and politicians worldwide.

The company said Epclusa will cost $74,760 for a 12-week course of treatment, or roughly $890 per pill. That’s less than the initial price for company’s previous drug, Harvoni, which cost $1,125 per pill. Gilead’s first hepatitis C drug, Sovaldi, cost roughly $1,000 per pill, touching off a national debate about escalating drug costs.

Since 2014, the FDA has approved rival medications from AbbVie Inc., Merck & Co., and Bristol-Myers Squibb Co. that have helped curb prices.

Read Full Article: FDA approves first pill to treat all forms of hepatitis C | Health News | US News

Read Full Article: FDA approves first pill to treat all forms of hepatitis C | Health News | US News

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.